Corbus Pharmaceuticals to present Phase 1 clinical data for SYS6002

Corbus Pharmaceuticals announced that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 has been released, and the corresponding up-to-date data will be presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023. The study is being conducted by Corbus’s partner CSPC Pharmaceutical Group in China. ASCO GU will be held January 25-27, 2024 in San Francisco, CA and online. The abstract, a Phase 1 Dose-Escalation of SYS6002, a next-generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al will be presented on Jan 26th between 11:30-1pm PST. SYS6002 is currently being explored in a dose escalation on a Q3W schedule, with a view to reducing free-MMAE concentrations in plasma and thereby reducing the associated toxicities that are known to dose limit enfortumab vedotin. Additionally, by administering SYS6002 on a Q3W schedule there is an opportunity to increase clinical convenience and patient compliance. The dose escalation that will be presented currently spans 6 dose levels and makes use of a Bayesian Optimal Interval design with accelerated titration. The trial is evaluating the safety and tolerability of SYS6002 to determine the Maximum Tolerated Dose and/or the Phase II dose in patients with advanced solid tumors who have failed or were intolerant to standard treatment. Patients were enrolled based on nectin-4 staining, with the exception of metastatic urothelial cancer urothelial cancer patients, who were considered to be nectin-4 positive. Beyond determining safety and tolerability, the pharmacokinetic and preliminarily anti-tumor activity of SYS6002 are reported. The Poster will include an updated cumulative dataset, based on a data-cut of 18 December 2023, of safety, tolerability, preliminary anti-tumor activity, pharmacokinetic, and nectin-4 expression levels from patients with metastatic urothelial cancer, cervical cancer, triple-negative breast cancer, and colorectal cancer. Continued development of SYS6002 as both a monotherapy and in combination is planned both in China, U.S. and Europe.